Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana
- PMID: 32160214
- PMCID: PMC7065819
- DOI: 10.1371/journal.pone.0229500
Mid-trimester cervical length not associated with HIV status among pregnant women in Botswana
Abstract
Objective: HIV-infected women on antiretroviral therapy have a higher risk of preterm birth than HIV-uninfected women in Botswana. To better understand the mechanism for preterm birth among HIV-infected women, we evaluated whether mid-trimester cervical length differed by HIV status as cervical shortening is associated with an increased risk for preterm birth.
Methods: We conducted a prospective cohort study among pregnant women receiving care at the Scottish Livingstone Hospital in Molepolole, Botswana. Consecutive women referred for routine obstetrical ultrasound were consented and enrolled if between 22w0d and 24w6d by ultrasound biometry. Blinded to maternal HIV status, an obstetrician measured transvaginal cervical length using standardized criteria. Cervical length, as well as the proportion of women with a short cervix (<25mm), were compared among HIV-infected and HIV-uninfected women. The acceptability of transvaginal ultrasound was also evaluated.
Results: Between April 2016 and April 2017, 853 women presenting for obstetric ultrasound were screened, 187 (22%) met eligibility criteria, and 179 (96%) were enrolled. Of those enrolled, 50 (28%) were HIV-infected (86% on antiretroviral therapy), 127 (71%) were HIV-uninfected, and 2 (1%) had unknown HIV status. There was no significant difference in mean cervical length between HIV-infected and HIV-uninfected women (32mm vs 31mm, p = 0.21), or in the proportion with a short cervix (10% vs 14%, p = 0.44). Acceptability data was available for 115 women who underwent a transvaginal ultrasound exam. Of these, 112 of 115 (97%) women deemed the transvaginal scan acceptable.
Conclusions: The increased risk of preterm birth observed among HIV-infected women receiving antiretroviral therapy in Botswana is unlikely associated with mid-trimester cervical shortening. Further research is needed to understand the underlying mechanism for preterm birth among HIV-infected women.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Prediction of spontaneous preterm birth by cervical length in the first trimester of pregnancy: Comparison of two measurement methods.Acta Obstet Gynecol Scand. 2021 Jul;100(7):1305-1312. doi: 10.1111/aogs.14138. Epub 2021 Mar 30. Acta Obstet Gynecol Scand. 2021. PMID: 33683725
-
Beyond Cervical Length: Association between Postcerclage Transvaginal Ultrasound Parameters and Preterm Birth.Am J Perinatol. 2019 Nov;36(13):1317-1324. doi: 10.1055/s-0039-1688480. Epub 2019 Apr 30. Am J Perinatol. 2019. PMID: 31039598 Free PMC article.
-
A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate.Am J Obstet Gynecol. 2016 Mar;214(3):365.e1-5. doi: 10.1016/j.ajog.2015.12.020. Am J Obstet Gynecol. 2016. PMID: 26928150
-
Cervical assessment.Best Pract Res Clin Obstet Gynaecol. 2025 Mar;99:102590. doi: 10.1016/j.bpobgyn.2025.102590. Epub 2025 Mar 11. Best Pract Res Clin Obstet Gynaecol. 2025. PMID: 40090290 Review.
-
Transvaginal sonographic examination of the cervix in asymptomatic pregnant women: review of the literature.Ultrasound Obstet Gynecol. 2002 Mar;19(3):302-11. doi: 10.1046/j.1469-0705.2002.00645.x. Ultrasound Obstet Gynecol. 2002. PMID: 11896957 Review.
Cited by
-
Adverse perinatal outcomes associated with antiretroviral therapy in women living with HIV: A systematic review and meta-analysis.Front Med (Lausanne). 2023 Feb 3;9:924593. doi: 10.3389/fmed.2022.924593. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36816720 Free PMC article.
-
Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women.Lancet Infect Dis. 2023 Apr;23(4):e151-e159. doi: 10.1016/S1473-3099(22)00687-9. Epub 2022 Nov 11. Lancet Infect Dis. 2023. PMID: 36375478 Free PMC article. Review.
-
Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy.Expert Rev Anti Infect Ther. 2022 Jun;20(6):837-848. doi: 10.1080/14787210.2022.2046463. Epub 2022 Mar 1. Expert Rev Anti Infect Ther. 2022. PMID: 35196941 Free PMC article. Review.
References
-
- Stiehm E. R. et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J. Infect. Dis. 179, 567–575 (1999). 10.1086/314637 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous